April 16, 2021
Article
The FDA approved nivolumab (Opdivo) plus certain types of chemotherapy for the treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction (GEJ) cancer, and esophageal adenocarcinoma.
April 15, 2021
The FDA has granted a rare pediatric disease designation to the p-STAT3 inhibitor WP1066 for the treatment of patients with ependymoma, a rare type of tumor that can develop in the brain or the spinal cord.
April 13, 2021
The FDA granted an accelerated approval to sacituzumab govitecan (Trodelvy) for patients with locally advanced or metastatic urothelial cancer (mUC) who previously had a platinum-containing chemotherapy and a PD-1 or PD-L1 inhibitor.
An Arkansas law may lay the groundwork for unfair care in certain populations, but there are always nurses and other clinicians ready to advocate for all of their patients.
April 12, 2021
The FDA has authorized the marketing of the first device that utilizes artificial intelligence based on machine learning to help clinicians detect lesions like polyps or suspected tumors in the colon in real time during a colonoscopy.
Lifileucel produced durable responses in advanced melanoma that was previously treated an an immunotherapy agent.
April 09, 2021
Caregivers have their own set of issues and anxieties, but a telehealth support service may help.
April 08, 2021
The information provided by the assessment is essential as it contributes to shared decision making. The goal of shared decision-making is for patients and clinicians to partner together and make informed choices based on the patient’s needs, values and preferences.
April 07, 2021
Wearable fitness trackers may boost fitness, quality of life and overall health in childhood cancer survivors.
The FDA has approved a new biweekly dosing regimen of 500 mg/m2 as a 120-minute intravenous infusion for cetuximab (Erbitux) for patients with KRAS wild-type, EGFR-expressing colorectal cancer or squamous cell carcinoma of the head and neck.
